[Reply to Letter to the Editor in reference to " Clinical and economic evaluation of the introduction of the combinazion trametinib + dabrafenib in the management of advanced melanoma in the Italian market”]

Lorenzo Pradelli, Paolo Ascierto

DOI: https://doi.org/10.7175/fe.v18i1.1329

Full Text

HTML PDF

Statistics

Abstract: 1011 views
HTML: 220 views
PDF: 287 views

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.